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Abstract  
GDNF supports function and survival of dopamine neurons that degenerate in Parkinson’s disease (PD). 
Ectopic delivery of GDNF in clinical trials to treat PD is safe but lacks significant therapeutic effect. In pre-
clinical models, ectopic GDNF is effective but causes adverse effects including downregulation of tyrosine 
hydroxylase, only a transient boost in dopamine metabolism, aberrant neuronal sprouting and 
hyperactivity. Hindering development of GDNF mimetic, increased signalling via GDNF receptor RET by 
activating mutations results in cancer. To develop successful GDNF-based therapies, safe and effective 
mode of action must be defined first in animal models. Previously we showed that about a two-fold 
increase in endogenous GDNF expression is safe and results in increased motor and dopaminergic function 
and protection in PD model in young animals. Recently, similar results were reported using a novel Gdnf 
mRNA-targeting strategy. Next, it is important to establish safety of long-term increase in endogenous 
GDNF expression. We report behavioural, dopamine system and cancer analysis of five cohorts of aged 
mice with two-fold increase in endogenous GDNF. We found sustained increase in dopamine levels, 
improvement in motor learning and no side-effects or cancer. These results support rationale for further 
development of endogenous GDNF-based treatments and GDNF mimetic.  
Introduction 
Glial cell line-derived neurotrophic factor (GDNF) protects and promotes the survival and function of 
midbrain dopaminergic neurons in cell culture1 and in animal models of Parkinson’s disease (PD)2. 
Intracranial ectopic delivery of GDNF has been tested in clinical trials for PD. Most of the studies conducted 
on PD patients reported an increased putamenal 18Fluoro-dopamine uptake, suggesting a neurotrophic 
effect3-8. However, major concern is the lack of clinical benefit upon GDNF delivery into the brain3-11. 
Results from the most recent double-blind, placebo-controlled phase II trial showed no significant 
improvements in PD patients where GDNF was delivered into the putamina once per month for 40 weeks 
compared to the placebo group3. Notably however, a post-hoc analysis revealed that 9 (43%) patients who 
were treated with GDNF, but no placebo patients, demonstrated a significant motor improvement in the 
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OFF state3, providing hope for late onset efficacy. The same patients who participated in the study also 
took part in a second open-label phase of the trial where all received monthly infusions of GDNF for 
another 40 weeks4. Results showed significant improvements in both groups, again suggesting that GDNF 
may offer hopes for PD patients, although any conclusions derived from the second part of the trial must 
take into account that the trial was not placebo-controlled4. At the time of this writing, a trial of adeno-
associated virus, serotype-2 (AAV2) vector delivering GDNF in the putamina of subjects with advanced PD is 
ongoing. However, while results from phase I study reported no side effects, AAV2-GDNF delivery also had 
no effect on the progression of PD evaluated until 18 months post-infusion5.  
Contrary to the clinical trials, in PD preclinical models ectopically delivered GDNF is effective2, 12-15. 
However, efficacy comes with side effects.  Nigrostriatal delivery of ectopic GDNF results in a decrease in 
striatal and nigral levels of tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine 
biosynthesis16-18, aberrant arborization of striatal dopaminergic fibres towards the GDNF injection site due 
to non-physiological chemoattraction18-20, hyperactivity19, 21-23, loss of body weight24 and only a transient 
elevation in dopamine turnover for a few months upon viral delivery 16, 19, 23. All of these, alone or in 
combination, may emerge once efficacy in humans is achieved and are likely to present a clinical concern. 
Therefore, it is important to first establish safe mode of action in animal models. This objective formed the 
first rationale of our study.  
The second rationale of our study relates to the safety concern related to the development of GDNF 
mimetic which activates GDNF receptor RET (REarranged during Transfection)25. Activating mutations in 
RET result in early cancer syndrome named multiple endocrine neoplasia type 2 (MEN2) with tumors in 
thyroid, adrenal glands, and tongue26, 27, and GDNF overexpression in testes results in testicular cancer in 
mice28. Systemic application of GDNF mimetic to treat PD for years may therefore result in cancer. This 
concern has substantially reduced enthusiasm in developing GDNF mimetic. Our second objective was to 
analyze the long-term outcome of elevated endogenous GDNF expression on tumor formation. 
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Previously, we generated a mouse model where a constitutive, about two-fold elevation in endogenous 
GDNF levels was achieved by replacing the 3’ untranslated region (3’ UTR) of Gdnf with a 3’ UTR that is less 
responsive to inhibitory molecules such as microRNAs (GDNF hypermorphic mice, Gdnfwt/hyper)29. Because 
the 3’UTR-mediated regulation occurs at the post-transcriptional level, increase of endogenous GDNF levels 
in Gdnfwt/hyper mice is limited to the cells that naturally transcribe Gdnf. We found that young 10-week-old 
Gdnf
wt/hyper mice have improved motor coordination, enhanced dopamine system function, are protected in 
chemically induced model of PD and do not display adverse outcomes related to ectopic GDNF 
overexpression29, 30. Very recently, others used long non-coding RNAs to enhance endogenous GDNF 
protein translation and reached similar conclusion in young animals31.  In order to proceed with 
endogenous GDNF-based drug development and GDNF mimetic research, a preclinical safety evaluation of 
long-term elevation of endogenous GDNF is important. Chronic elevation in endogenous GDNF may trigger 
side effects similar to ectopic GDNF during longer time period, trigger new side effects such as 
neuropsychiatric conditions that relate to chronically elevated striatal dopamine32-35 or result in cancer. 
Here we report the results of analysis of five cohorts of aged Gdnfwt/hyper mice and wild-type gender-
matched littermate controls for dopamine system, multiple behavioral endpoints covering dopamine 
related brain functions, and cancer formation. 
Results 
This study was designed to investigate the outcome of a long-term, about two-fold increase in endogenous 
GDNF levels by analyzing aged Gdnfwt/hyper mice and wild-type littermate controls. We used a set of 
behavioral tests to evaluate motor function and other endpoints that associate with changes in GDNF levels 
and brain dopamine system. At the endpoint of about 19 months of age, mice were analyzed for various 
brain dopamine system parameters and for tumor formation. An overview of the side effects and 
physiological functions which associate with dopamine system and with GDNF/RET signalling analysed in 
this study is depicted in Figure 1.  
Analysis of motor function and learning in aged Gdnf
wt/hyper 
mice 
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Behavioral analysis of Gdnfwt/hyper mice using gender-matched littermates as controls was initiated at 15-17 
months of age and concluded by 17-19 months of age. Quantitative PCR (QPCR) analysis revealed a similar 
about two-fold increase in Gdnf mRNA levels in old Gdnfwt/hyper mice, as reported previously in young 
Gdnf
wt/hyper animals (Figure 2A)29. Ectopic GDNF overexpression in the nigrostriatal tract has been reported 
to cause a loss in body weight24, which may influence outcome of motor tests. We observed no difference 
in body weight between Gdnfwt/wt and Gdnfwt/hyper mice (Figure 2B). First, old Gdnfwt/wt and Gdnfwt/hyper mice 
were analyzed with a variety of tests that evaluate motor coordination and learning under forced 
movement conditions. We performed an accelerating rotarod test, on two consecutive days, with three 
trials per day. The performance of Gdnfwt/hyper mice improved significantly on day 2 (Figure 2C). Notably on 
day 2 aged Gdnfwt/hyper animals performed as well as untrained (day 1) young wild-type mice at 10 weeks of 
age in a comparable genetic background (Figure 2C, dotted line)30. Next, we performed the vertical grid 
test, which evaluates motor function and the righting-reflex. Time to turn upward, to climb to the upper 
edge and to fall off the grid were measured with one trial per day for two consecutive days. We found that 
Gdnf
wt/hyper animals turn faster on day 1, and have a faster learning curve compared to controls at day 2 
(Figure 2D). This is consistent with observed increase in motor learning in the rotarod experiment. In 
addition, Gdnfwt/hyper mice reached the upper edge of the grid faster (Figure 2E) and none of the Gdnfwt/hyper 
mice fell off the grid during the experiment (Figure 2F). Thus, constitutively increased endogenous GDNF 
levels do not cause changes in body weight but improve motor learning and the righting-reflex in 15-17 
months old mice. 
Analysis of voluntary motor behaviour and muscle strength in aged Gdnf
wt/hyper 
mice 
Next, we performed tests to investigate voluntary motor behaviour of Gdnfwt/wt and Gdnfwt/hyper mice. First, 
we performed the beam walking test. No differences were recorded between Gdnfwt/wt and Gdnfwt/hyper mice 
(Figure 3A, B). We then investigated motor coordination and balance in the multiple static rod test, which 
consists of a series of five wooden rods of decreasing diameters. The latencies to turn to face the fixed end 
of the rod and then to travel to the supporting beam were recorded, no differences were detected 
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between genotypes (Figure 3C, D). Because muscle strength may influence the outcome of motor tests, we 
measured this parameter. In the coat hanger test, we observed no difference between genotypes in the 
coat hanger score, latency to reach the lines, and latency to fall (Figure 3E, F, G, and see Materials and 
Methods for details). Similar results were obtained in forelimb grip strength test (Figure 3H). Our data 
suggest that motor balance under voluntary movement conditions and muscle strength in aged Gdnfwt/hyper 
mice is comparable to their wild-type littermates.  
Analysis of dopamine system and related functions in aged mice Gdnf
wt/hyper
 mice 
We measured total tissue dopamine levels in the striatum of Gdnfwt/wt and Gdnfwt/hyper animals using high 
performance liquid chromatography. We detected increased striatal dopamine levels in Gdnfwt/hyper mice 
(Figure 4A), while the levels of main dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), were unaltered (Figure 4B, C). Next, we counted the number of dopamine cells in 
the Substantia Nigra pars compacta (SNpc) and analysed dopaminergic fibres in the dorsal Striatum (dSTR) 
by TH-immunostaining in Gdnfwt/wt and Gdnfwt/hyper mice (Figure 4F). We found a small but significant 
increase in the number of dopamine neurons in the SNpc of Gdnfwt/hyper animals (Figure 4D). The intensity 
and pattern of TH-immunostaining in the dSTR did not significantly differ between the genotypes (Figure 
4E). Th mRNA levels in the dSTR and SN did not differ between Gdnfwt/wt and Gdnfwt/hyper mice (Figure 4G). 
Our results indicate that about two-fold life-long increase of endogenous GDNF increases striatal dopamine 
levels and the number of dopamine neurons in the SNpc without affecting the level of Th mRNA in the dSTR 
and SN and without causing aberrant sprouting of TH-positive fibres. 
Nigrostriatal recombinant GDNF injection results in hyperlocomotion19, 21-23 and genetic modifications or 
drugs that increase dopamine and dopamine transmission cause hyperactivity36-39, and induce anxiety34, 35. 
We did not observe difference in the distance travelled or time spent in the centre of the arena in open 
field test, suggesting lack of hyperlocomotion and anxiety-like behaviours in Gdnfwt/hyper animals respectively 
(Figure 4H, I). Enhanced striatal dopamine function is associated with schizophrenia32, 33. We measured 
sensorimotor gating using the prepulse inhibition (PPI) test, a parameter altered in schizophrenic patients 
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and mice with a schizophrenia-like phenotype40, 41 and found no difference between genotypes (Figure 4J). 
Ectopic overexpression of GDNF in the hippocampus of aged rats improves cognitive function42, and 
reduced levels of endogenous GDNF in Gdnf knock-out (KO) heterozygous mice affect learning performance 
in the Morris water maze test43. Analysis of animals using Morris water maze test revealed no difference in 
spatial learning and memory between genotypes (Figure 4K, L). Thus, despite the sustained increase in 
striatal dopamine levels, an about two-fold constitutive elevation of endogenous GDNF does not result in 
enhanced spontaneous locomotion or anxiety, impaired sensorimotor gating, or alteration in spatial 
learning or memory in aged Gdnfwt/hyper mice.    
Analysis of cancer in aged Gdnf
wt/hyper
 mice 
Overexpression of GDNF in the testes causes seminomatous germ cell tumours in 100% of mice by 12 
months of age28. Mutations resulting in constitutive activation of GDNF receptor RET, convert the RET gene 
into an oncogene44. The resulting condition, multiple endocrine neoplasia type 2B (MEN2B), triggers 
tumours in endocrine organs, most prominently in the thyroid (C-cell hyperplasia) and adrenal glands 
(chromaffin cells hyperplasia) as well as in the tongue 27. In a mouse model genocopying the MEN2B 
Met918Thr mutation, tumours appear between 2-5 and 8-12 months of age in MEN2B homozygous and 
heterozygous mice, respectively 26. Anatomical and histopathological evaluation of the adrenal glands, 
thyroid, tongue and testes of 17-19 months old Gdnfwt/wt and Gdnfwt/hyper mice revealed no cancer, neoplasia 
or abnormal cell masses (Figure 5A, B). Anatomical evaluation of other organs including liver, spleen, 
kidneys and eyes detected no tumours (Figure 5B). The observed histological alterations were sporadic and 
characteristic of old age (Figure 5B). 
Discussion 
Previously we reported that about a two-fold elevation of endogenous GDNF levels increases motor 
coordination and brain dopamine function without side effects in young mice29, 30. This conclusion was 
recently confirmed by others31, suggesting that means to elevate endogenous GDNF expression may 
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constitute a safe and efficient treatment route for PD. One possible way to stimulate GDNF signalling are 
GDNF mimetic, i.e. small molecule GDNF receptor RET agonists which penetrate the blood-brain barrier 
(BBB) and can be delivered systemically. However, constitutively activating mutations in RET result in 
multiple endocrine neoplasia26, 27, posing a serious safety concern for potential future chronic application of 
GDNF mimetic. Before making substantial investment into developing GDNF mimetic it would therefore be 
important to analyse the long-term outcome of chronic increase in endogenous GDNF. If, similarly to 
mutations in RET with consequent constitutive activation of RET signalling, chronic increase in GDNF results 
in multiple endocrine neoplasia, investment into GDNF mimetic would hardly be rational. Likewise, another 
critical organ are the testes, where ectopic GDNF overexpression results in cancer in mice28. Very recently, 
hematopoietic stem cell transplantation-based macrophage-mediated GDNF delivery was shown to be 
effective and safe in a mouse model of PD45. Cheng and colleagues45 reported that about five months after 
GDNF delivery, no tumors were found, although a need for long-term evaluation with a focus on MEN2 
organs was noted by the authors45. Increased endogenous GDNF may also result in new side-effects that 
only manifest upon chronic increase in endogenous GDNF expression upon aging. We hypothesized that 
upon aging some adverse effects reported for ectopic GDNF will possibly appear in Gdnfwt/hyper mice and 
that we will likely detect new side-effects or MEN2-like neoplastic changes or cancer. To our surprise, we 
found no adverse effects. Instead, aged Gdnfwt/hyper mice showed increased motor learning and 
performance in accelerating rotarod and vertical grid tests. After one day of training, the performance level 
of aged Gdnfwt/hyper mice was comparable to that of young 10-week-old wild-type mice. How a constitutive 
increase in endogenous GDNF expression increases motor learning and function until high age remains 
currently unknown, but is an interesting subject of future inquiry. Endogenous GDNF is expressed in several 
central nervous system (CNS) regions and cell types that regulate motor function including striatum29, 46, 
motor cortex, cerebellum, and spinal cord47-50. Future investigation, including generation and analysis of 
conditional GDNF hypermorphic mice, may reveal in which of the above-mentioned CNS regions and how 
an elevation of endogenous GDNF is responsible for increased motor learning and function in aged animals. 
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We also found that aged Gdnfwt/hyper mice display sustained elevation in striatal tissue dopamine levels and 
a sustained increase in the number of dopamine cells in the SNpc with no evidence for Th mRNA 
downregulation or aberrant sprouting of TH-positive dopamine fibres in the striatum. We noticed variability 
in Th mRNA expression levels, especially in the substantia nigra. However, analysis of striatal dopamine 
level and number of TH-positive cells in the substantia nigra followed by measurement of striatal TH-
positive fibres suggest that TH protein function and level remain in physiological range despite the 
observed alterations at mRNA level. A small but non-significant trend for an increase in TH-positive fibres in 
Gdnf
wt/hyper
 animals likely reflects small but significant increase in dopamine cell numbers in the substantia 
nigra. We also found no decrease in body mass or hyperlocomotion in Gdnfwt/hyper mice. Because dopamine 
neurons are the main RET-expressing neurons in the CNS, and dopamine neurons in mice lacking RET do 
not respond to GDNF and in vitro and in vivo51, 52, we hypothesize that GDNF mediates those effects via RET 
receptor as opposed to other two reported receptors for GDNF in the CNS - neural cell adhesion molecule 
(NCAM) and Syndecan-353, 54. Unfortunately, quantitative analysis of RET phosphorylation in vivo in the 
brain is very challenging and many laboratories, including ours, have failed to generate reproducible 
results, leaving quantitation of RET activation in Gdnfwt/hyper animals a future challenge. 
The effects of long-term ectopic and endogenous GDNF elevation are summarized in Table 1. Our 
previous29, 30 and current results suggest that constitutive about two-fold elevation of endogenous GDNF is 
safe and enhances dopamine system function, improves motor performance, and may overcome the 
adverse effects associated with ectopic overexpression. Our results encourage future studies on increased 
endogenous GDNF using various means29-31, 55, support further development of recently created GDNF 
mimetic25, 56 and encourage other means of moderate GDNF application including macrophage-mediated 
GDNF delivery45. 
Materials and Methods 
Animals 
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Mice were 15-17 months old when the behavioural experiments started and 17-19 months old by the end 
of the experiments. Because oestrus cycle is believed to enhance experimental variation and because of the 
considerable costs of aging studies we analysed only male mice. However, in our previous study30 we 
observed improved motor coordination in young Gdnfwt/hyper male mice and a trend for improved motor 
coordination in young female mice30. In the future it would be of great interest to analyse female mice for 
the same parameters. Wild-type littermates were used as controls in all experiments. Animals were 
maintained in 129Ola/ICR/C57bl6 mixed genetic background and maintained at temperature-controlled 
conditions at 20-22º C under 12h/12h light/dark cycle at relative humidity of 50-60%. Cages and bedding 
material (aspen chips, Tapvei Oy, Finland) were changed every week, and wooden tube and aspen shavings 
were provided as enrichment. Mice received food and water ad libidum. Altogether, five cohorts of mice 
were used in this study for a total of 80 animals (41 Gdnfwt/wt and 39 Gdnfwt/hyper mice). The experiments 
performed in each cohort are listed below (abbreviations are explained in the paragraphs below).  
• Cohort 1 (7 Gdnfwt/wt + 7 Gdnfwt/hyper): all the behavioural tests listed below (except MSR), HPLC, TH 
immunohistochemistry and stereological analysis of TH-positive cells in the SNpc. 
• Cohort 2 (6 Gdnf wt/wt + 4 Gdnf wt/hyper): all the behavioural tests listed below and striatal optical 
density measurement of TH-positive fibres. 
• Cohort 3 (12 Gdnfwt/wt + 9 Gdnfwt/hyper): all the behavioural tests listed below and gene expression 
analyses via qPCR (7 Gdnfwt/wt + 7 Gdnfwt/hyper). 
• Cohort 4 (12 Gdnfwt/wt + 12 Gdnfwt/hyper): post-mortem anatomical and histopathological evaluation 
of the testes.  
• Cohort 5 (4 Gdnfwt/wt + 7 Gdnfwt/hyper): post-mortem anatomical analysis of liver, spleen, kidneys, and 
eyes and histopathologic evaluation of adrenal glands, thyroid, tongue, and testes. 
All experiments were conducted following the 3R principles of the EU directive 2010/63/EU governing the 
care and use of experimental animals and were approved by the County Administrative Board of Southern 
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Finland (licence numbers ESAVI-2010-09011/Ym-23 and ESAVI/11198/04.10.07/2014). The protocols were 
authorized by the national Animal Experiment Board of Finland. 
Behavioral tests 
Behavioral tests including rotarod, vertical grid, beam walking, coat hanger, grip strength, open field, and 
prepulse inhibition were performed as described previously in 30. 
Multiple static rods (MSR) 
The multiple static rods test was performed to investigate motor coordination and balance. The multiple 
static rods are series of five 60 cm long wooden rods of decreasing diameters (rod 1 - 27 mm; rod 2 - 21 
mm; rod 3 - 15 mm; rod 4 - 11 mm; and rod 5 - 8 mm), each perpendicularly screwed at one end to a 
supporting beam. The apparatus was elevated 60 cm above a soft surface. The animal was placed 2 cm 
from the distal end of the rod, facing away from the supporting beam. The latencies to turn to face the 
fixed end of the rod, and then to travel to the supporting beam, were recorded in a period of max. 3 
minutes. 
Morris water maze (MWM) 
The Morris water maze was used to evaluate spatial learning and memory. The system consisted of a black 
circular swimming pool (Ø 120 cm) and an escape platform (Ø 10 cm) submerged 0.5 cm under the water 
surface in the centre of one of four imaginary quadrants. The animals were released to swim in random 
positions facing the wall and the time to reach the escape platform (maximum time 60 s) and the swimming 
distance were measured in every trial. In addition, thigmotaxis, the time spent swimming within the 
outermost ring of the pool (10 cm from the wall), was measured. Two training blocks consisting of three 
trials each were conducted daily. The interval between trials was 4-5 min and between training blocks 
about 5 hours. The hidden platform remained in a constant location for 3 days (six initial training sessions) 
and was thereafter moved to the opposite quadrant for 2 days (four reverse training sessions). Probe trials 
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were conducted approximately 18 h after the last initial and reverse training sessions. Mice were allowed 
to swim in the maze for 60 seconds without the platform available. Spatial memory in the probe trials was 
estimated by preference of swimming in the trained region (imaginary circular area of Ø 30 cm, around the 
previous platform location) over swimming in corresponding regions in the three other quadrants. After the 
second probe trial, the mice were tested for one block of three trials with the platform made visible in the 
quadrant not employed previously. 
Tissue isolation 
After deep anaesthesia with CO2, mice were euthanized by cervical dislocation followed by decapitation. 
The brain was quickly removed from the skull, immersed in ice-cold saline, and placed in an ice-cooled 
brain block (Stoelting, Wood Dale, IL). Brain regions of interest were collected as described in 29 using a 
puncher (inner diameter 2mm), snap frozen, and stored at -80 °C until processed.  
RNA isolation and quantitative PCR 
Total RNA was isolated from frozen tissues using Trizol Reagent (Thermo Fisher Scientific) according to the 
manufacturer’s protocol and RNA quantity and quality (absorbance 260/280 nm>1.8) were assessed using a 
NanoDrop (NanoDrop Technologies, LLC, Wilmington, DE, USA). 200 ng of DNase I (Thermo Fisher Scientific, 
MA, USA)-treated total RNA was reverse transcribed to complementary DNA using random hexamer 
primers and RevertAid Reverse Transcriptase (Thermo Fisher Scientific, MA, USA). Complementary DNA 
was diluted 1:10 and stored at -20 °C until analysis. Quantitative PCR was performed with BioRad C1000 
Touch Thermal Cycler upgraded to CFX384 System (BioRad), supplied with SYBR Green I Master (Roche) and 
250 pmol primers, in 10 μl total volume in 384-well plates. The following primer pairs were used: Gdnf (F: 5' 
CGCTGACCAGTGACTCCAATATGC 3', R: 5' TGCCGCTTGTTTATCTGGTGACC 3'), Th (F: 5' 
CCCAAGGGCTTCAGAAGAG 3', R: 5' GGGCATCCTCGATGAGACT 3'), Actb (F: 5' CTGTCGAGTCGCGTCCA 3', R: 5' 
ACGATGGAGGGGAATACAGC 3'), Gapdh (F: 5' CCTCGTCCCGTAGACAAAA 3', R: 5' 
ATGAAGGGGTCGTTGATGGC 3'), Pgk1 (F: 5' TTGGACAAGCTGGACGTGAA 3', R: 5' AACGGACTTGGCTCCATTGT 
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3'). Each sample was run in triplicate. Expression level of Gdnf was normalized to Actb housekeeping gene 
expression level and expression level of Th was normalized to Actb and to the geometric mean of Actb, 
Gapdh, and Pgk1 housekeeping genes expression level. Both reference systems for Th revealed similar 
result, and data using geometric mean of Actb, Gapdh, and Pgk1 as reference is presented on Figure 4G. 
Results for a biological repeat were discarded when the Cq value for one or more of the replicates was 40 or 
0, or when the Cq difference between replicates was >1. 
High performance liquid chromatography (HPLC) 
Monoamines and their respective metabolites were analysed from the dissected brain samples as 
described previously 57 using HPLC with electrochemical detection. The values are presented as nanograms 
per gram of wet tissue weight. 
TH Immunohistochemistry  
For striatal optical density measurement of TH-positive fibres (cohort 2), mice were anesthetized with 
sodium pentobarbital (100mg/kg, i.p.) and intracardially perfused with PBS followed by 4% PFA in 0.1 M 
phosphate buffer, pH 7.4. The brains were then fixed in 4% PFA overnight, and stored in phosphate buffer 
containing 20% sucrose at 4°C. For striatal dopamine level measurement and TH immunohistochemistry 
(cohort 1), an alternative ‘light’ perfusion method was used. Briefly, the brains were cooled after PBS 
perfusion and dorsal striatum was dissected from the rostral part of the brain for HPLC analysis, while the 
posterior part containing the midbrain was fixed overnight in 4% PFA for stereological analysis of TH-
positive cells in the SNpc. Coronal striatal (30 µm) and nigral (40 µm) serial sections were cut using a 
freezing microtome and stored at -20°C until processed for TH immunostaining. Staining of freely floating 
brain sections was performed using standard immunohistochemical procedures, and the following 
antibodies were used: rabbit-anti-TH (1:2000; AB 152, Millipore), and biotinylated goat-anti-rabbit (1:200; 
BA1000, Vector Laboratories). Vectastain Elite ABC peroxidase kit (Vector Laboratories) was used for 
visualization. Further details are provided in 58. 
15 
 
Stereological analysis of TH-positive cells 
The number of TH-positive neurons in the SNpc was assessed by a person blinded to the identity of the 
samples, as described in 29. Briefly, cells positive for TH were counted at the medial region of the SNpc, 
around the medial terminal nucleus. From each animal, every third section between −3.08 and −3.28 mm 
caudally from bregma was selected (3 sections per animal). StereoInvestigator (MBF Bioscience) was used 
to outline the SNpc, and positively stained cells were counted within the defined outlines according to the 
optical dissector rules. Cells were counted at regular predetermined intervals (x = 100 μm; y = 80 μm) 
within the counting frame (60 μm × 60 μm) superimposed on the image using a 60× oil objective [Olympus 
BX51 (Olympus Optical) equipped with an Optronics camera]. The counting frame positions within the SNpc 
were randomized by the software. The coefficient of error (CE) was calculated as an estimate of precision 
and values <0.1 were accepted. Failure in staining or perfusion resulting in spoiled sections was an 
exclusion criterion. 
Striatal optical density (OD) measurement 
A person who was blinded to the identity of the genotypes performed the OD analysis of the striata of 
Gdnf
wt/wt
 and Gdnfwt/hyper mice. Images were generated using 3DHISTECH Pannoramic 250 FLASH II digital 
slide scanner at Genome Biology Unit supported by HiLIFE and the Faculty of Medicine, University of 
Helsinki, and Biocenter Finland. Measurements of striatal TH-positive fibres were performed using Fiji Is 
Just ImageJ (ImageJ, Version 1.52) 59. Image calibration was done by using a calibrated OD step tablet 
containing 21 steps with a density range of 0.05 to 3.05 OD. Analysis was done from five to six striatal 
sections from each animal and the final reading was calculated as an average. Dorsal and ventral striatum 
were analysed separately and the nonspecific background correction in each section was done by 
subtracting the OD value of the corpus callosum from the striatal OD value of the same section. Failure in 
staining or perfusion resulting in spoiled sections was an exclusion criterion.  
Histopathology 
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Mice were autopsied at 17-19 months of age. Anatomical evaluation of mice upon autopsy and 
histopathological assessment of tissues associated with GDNF/RET signaling-induced cancer (thyroid, 
adrenal glands, tongue, and testes) and four control organs selected at random for detailed examination 
(liver, spleen, eyes, and kidneys) was performed by a professional pathologist at the Finnish Centre for 
Laboratory Animal Pathology (FCLAP), Faculty of Veterinary Medicine, University of Helsinki. The tissue 
samples were fixed in phosphate-buffered 4% paraformaldehyde or 4% formaldehyde and routinely 
processed into histological slides: dehydrated, embedded in paraffin, and sectioned at 4 µm thickness. All 
slides were stained with hematoxylin and eosin. Microscopic findings were classified with standard 
pathological nomenclature and severities of findings were graded as minimal, mild, moderate, marked, or 
severe. Grades of severity for microscopic findings are subjective. No tumours were found in the samples 
examined.  
Statistical analysis 
Comparisons between two groups were analysed with a Welch’s t-test or Mann-Whitney U-test. 
Comparisons between the same subjects were performed with a paired Student’s t-test. Analysis of rotarod 
test and prepulse inhibition test was performed with a two-way Analysis of Variance (ANOVA). Assessments 
with p < 0.05 were considered significant. 
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Figure legends 
Figure 1. An overview of side effects and physiological functions which associate with dopamine system 
function and/or with GDNF/RET signalling analysed in this study.  
Figure 2. Increased endogenous GDNF level improves motor learning in old Gdnf
wt/hyper
 mice. (A) Levels of 
Gdnf mRNA in the dorsal striatum (dSTR), substantia nigra (SN), and prefrontal cortex (PFC) of Gdnfwt/wt and 
Gdnf
wt/hyper mice quantified by quantitative PCR and normalized to Actb expression level. Welch’s t-test, 
p=0.0039 (dSTR), p=0.0015 (SN), and p=0.0060 (PFC). (B) Animal body weight before (START) and after 
(END) experiments. Welch’s t-test p=0.561 (START) and p=0.666 (END). (C) Latency to fall in accelerating 
rotarod test. ANOVA analysis comparing 15-17 months old Gdnfwt/wt and Gdnfwt/hyper animals (black and red 
lines, respectively) revealed significant genotype effect (Day 1 p=0.295, Day 2 p=0.009). ANOVA analysis 
comparing the performance between Day 1 and Day 2 within the same group showed significant 
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improvement in Gdnfwt/hyper animals (p=0.017), but not in wild-type littermates (p=0.081). The grey dotted 
line represents the rotarod performance of Gdnfwt/hyper mice tested in 30 at 10 weeks of age. (D) Latency to 
turn in the vertical grid test at Day 1 and Day 2 of the experiment. Welch’s t-test comparing Gdnfwt/wt and 
Gdnf
wt/hyper mice at Day 1 (p=0.041), Day 2 (p=0.01). Paired Student’s t-test comparing the latency to turn of 
Gdnf
wt/wt (p=0.758) and Gdnfwt/hyper mice (p=0.049) at Day 1 versus Day 2. (E) Latency to reach the top of the 
grid in the vertical grid test. Welch’s t-test, p=0.037. (F) Latency to fall of the grid in the vertical grid test. 
Welch’s t-test, p<0.001. Abbreviations: RR, rotarod; VG, vertical grid. (A) dSTR and SN: N= 6 Gdnfwt/wt and N 
= 7 Gdnfwt/hyper, PFC: N= 7 Gdnfwt/wt and N = 5 Gdnfwt/hyper. (B-F) N = 25 Gdnfwt/wt and N = 20 Gdnfwt/hyper. Data 
are presented as mean ± SEM. *p < 0.05. **p < 0.01 ***p < 0.001.   
Figure 3. Voluntary motor behaviour and muscular strength are not affected in aged Gdnf
wt/hyper 
mice. (A) 
Number of crossed lines during beam walking test. Welch’s t-test, p=0.319. (B) Latency to fall from the 
beam in the beam walking test. Mann-Whitney U-test, p=0.721. (C) Latency to turn on each rod in the 
multiple static rods test. Multiple t-test, Rod 1 (p=0.428), Rod 2 (p=0.652), Rod 3 (p=0.859), Rod 4 
(p=0.833), Rod 5 (p=0.304). (D) Time to reach the platform (escape and travel to the supporting beam) on 
each rod in the multiple static rods test. Multiple t-test, Rod 1 (p=0.517), Rod 2 (p=0.26), Rod 3 (p=0.374), 
Rod 4 (p=0.526), Rod 5 (p=0.404). (E) Score given in the coat hanger test. Welch’s t-test, p=0.652. (F) 
Latency to reach the lines in the coat hanger test. Welch’s t-test, Line 1 (end of horizontal part), p=0.458. 
Line 2 (diagonal part of the coat hanger), p=0.823. (G) Latency to fall off in the coat hanger test. Mann-
Whitney U-test, p=0.375. (H) Maximal forepaw pulling force measured in the grip strength test. Welch’s t-
test, p=0.06. Abbreviations: BW, beam walking; MSR, multiple static rods; CH, coat hanger. (A-B) and (E-H) 
N = 25 Gdnfwt/wt and N = 20 Gdnfwt/hyper. (B, C) N = 18 Gdnfwt/wt and N = 13 Gdnfwt/hyper. Data are presented as 
mean ± SEM. 
Figure 4. Sustained increase in GDNF and dopamine cell numbers and striatal levels in old Gdnf
wt/hyper
 
mice does not cause adverse effects. HPLC analysis of striatal (A) dopamine and its metabolites (B) DOPAC 
and (C) HVA. Welch’s t-test, p=0.016 (Dopamine), p=0.249 (DOPAC), p=0.359 (HVA). (D) TH-positive cell 
counts indicating the number of dopaminergic neurons in the SNpc of Gdnfwt/wt and Gdnfwt/hyper mice. 
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Welch’s t-test, p=0.03 (E) Striatal optical density measurement of TH-positive fibres in Gdnfwt/wt and 
Gdnf
wt/hyper mice. Welch’s t-test, p=0.095. (F) Representative coronal brain slices showing TH-
immunoreactive cell bodies in the SNpc (upper panel, low and higher magnification) and TH-
immunoreactive fibres in the striatum (lower panel, low and higher magnification of the dSTR) of Gdnfwt/wt 
and Gdnfwt/hyper mice. (G) Levels of Th mRNA in the dSTR and SN of Gdnfwt/wt and Gdnfwt/hyper mice quantified 
by quantitative PCR and normalized to the geometric mean of Actb, Gapdh, and Pgk1 expression level. 
Welch’s t-test, p=0.646 (dSTR) and p=0.898 (SNpc). (H) Total distance travelled in the open field test 
calculated in 5-minute blocks. Multiple t-test, 5 min (p=0.546), 10 min (p=0.300), 15 min (p=0.635), 20 min 
(p=0.593), 25 min (p=0.261), 30 min (p=0.491). (I) Time spent in the centre of the open field arena during 
the open field test calculated in 5-minute blocks. Multiple t-tests, 5 min (p=0.632), 10 min (p=0.767), 15 
min (p=0.834), 20 min (p=0.846), 25 min (p=0.875), 30 min (p=0.626). (J) Response to startle stimulus with 
different prepulse stimuli, relative to response to startle stimulus alone. Two-way repeated measures 
ANOVA test, genotype effect p=0.792. (K) Percentage of time spent in quadrants of the water maze during 
the probe trial 1 and (L) trial 2. Welch’s t-test, genotype effect probe 1 NE p=0.268, SE p=0.564, SW 
p=0.356, NW p=0.633. Probe 2 NE p=0.763, SE p=0.925, SW p=0.56, NW p=0.635. NE northeast, SE 
southeast, SW southwest, NW northwest. (T) indicates the quadrant that contained the escape platform 
during training. (A-C) N = 7 Gdnfwt/wt and N = 6 Gdnfwt/hyper. (D) N = 6 Gdnfwt/wt and N = 5 Gdnfwt/hyper. (E) N = 5 
Gdnf
wt/wt
 and N = 4 Gdnfwt/hyper. (G) dSTR: N = 6 Gdnfwt/wt and N = 6 Gdnfwt/hyper and SN: N = 7 Gdnfwt/wt and N 
= 7 Gdnfwt/hyper. (H-L) N = 25 Gdnfwt/wt and N = 20 Gdnfwt/hyper. Data are presented as mean ± SEM. *p < 0.05. 
** p < 0.01. 
Figure 5. Gdnf
wt/hyper
 mice do not develop multiple endocrine neoplasia or testicular tumours.  
(A) Representative 4µm thick slices from adrenal glands, thyroid, tongue, and testes. All slides were stained 
with hematoxylin and eosin. Scale bars are indicated in each image. (B) Main findings from anatomical and 
histopathological evaluation of different organs in 17-19 months old Gdnfwt/wt and Gdnfwt/hyper mice. 
Table 1 
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Main outcomes of elevated endogenous GDNF in aged Gdnf
wt/hyper
 mice. 
Phenotypes reported in 
previous studies 
Method Reference Long-term elevation of 
endogenous GDNF, this study 
Increase in dopamine 
turnover, but no changes 
in striatal dopamine tissue 
level 
 
Striatal or nigral recombinant 
lentiviral vector delivery of 
GDNF in unlesioned animals 
16 Elevated and sustained striatal 
dopamine levels 
Downregulation of TH 
levels in the STR and SN 
 
Striatal recombinant lentiviral 
vector delivery of GDNF 
16-18 No changes in TH levels in the 
STR and SN 
Striatal dopaminergic 
fibres sprouting towards 
GDNF injection site 
 
Nigrostriatal recombinant 
GDNF injection and viral gene 
delivery 
18-20 No increase of striatal TH-
positive dopaminergic fibres 
density 
Hyperactivity Nigrostriatal recombinant 
GDNF injection 
19, 21-23 No difference in spontaneous 
locomotor activity 
Loss in body weight Nigrostriatal virus-mediated 
GDNF delivery 
24 No change in body weight  
Tumours in testes in all 
mice used by 12 months of 
age 
 
Transgenic overexpression of 
GDNF in undifferentiated 
spermatogonia 
 
28 No tumours found in testes 
Thyroid and adrenal 
neoplasia 
GDNF receptor RET 
constitutive activation due to 
point mutation (MEN2B mice) 
26 No tumours found in thyroid 
and adrenal glands 
 
Ectopic GDNF delivery raises concerns about efficacy in clinical trials of Parkinson’s disease and safety 
issues in preclinical studies. Andressoo and colleagues showed that a long-term, two-fold increase in 
endogenous GDNF levels in mice is safe and improves motor and dopaminergic system function, supporting 
further development of endogenous GDNF-based therapies. 





